


PerCP/Cy5.5 anti-human IFN- γ

Catalog # / Size:	3112630 / 100 tests 3112625 / 25 tests
Clone:	4S.B3
Isotype:	Mouse IgG1, κ
Immunogen:	Partially purified, native human IFN- γ
Reactivity:	Human
Preparation:	The antibody was purified by affinity chromatography, and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).
Concentration:	Lot-specific



PMA+ionomycin-stimulated (6 hours) human peripheral blood lymphocytes intracellular stained with 4S.B3 PerCP/Cy5.5

Applications:

Applications:	Flow Cytometry
Recommended Usage:	Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cy5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Application Notes:	<p>ELISA or ELISPOT Detection⁵: The biotinylated 4S.B3 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified NIB42 antibody (Cat. No. 502402/502404) or purified MD-1 antibody (Cat. No. 507502/507513) as the capture antibody.</p> <p>Flow Cytometry^{3,4,6-8}: The fluorochrome-labeled 4S.B3 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ -producing cells within mixed cell populations.</p> <p>Additional reported applications (for the relevant formats) include: neutralization^{1,2}, Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated tissue sections, and immunocytochemistry. The 4S.B3 antibody can neutralize the bioactivity of natural or recombinant IFN-γ.</p> <p>Note: For testing human IFN-γ in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430101 to 430106) are specially developed and recommended.</p>
---------------------------	--

Application References:	<ol style="list-style-type: none"> Meager A, <i>et al.</i> 1984. <i>J. Interferon Res.</i> 4:619. (Neut) Meager A, 1987. <i>Lymphokines and Interferons: A Practical Approach.</i> IRL Press Ltd, Oxford, p. 105. (Neut) Sester M, <i>et al.</i> 2002. <i>J. Virol.</i> 76:3748. (ICFC) Infante-Duarte C, <i>et al.</i> 2000 <i>J. Immunol.</i> 165:6107. (ICFC) Goodier M, <i>et al.</i> 2000. <i>J. Immunol.</i> 165:139. (ELISA) Chen H, <i>et al.</i> 2005. <i>J. Immunol.</i> 175:591. (ICFC) Smeltz RB, 2007. <i>J. Immunol.</i> 178:4786. (ICFC)
--------------------------------	--

8. Iwamoto S, *et al.* 2007. *J. Immunol.* 179:1449. (ICFC) [PubMed](#)
9. Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (ICFC)
10. Bacher P, *et al.* 2014. *J Immunol.* 193:3332. [PubMed](#)
-

Description: Interferon- γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN- γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN- γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

**Antigen
References:** 1. Fitzgerald K, *et al.* Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, *et al.* 1992. *Curr. Opin. Immunol.* 4:321.
3. Farrar M, *et al.* 1993. *Annu. Rev. Immunol.* 11:571